SEARCH

SEARCH BY CITATION

References

  • Alexandrescu, D.T., McClure, R., Farzanmehr, H. & Dasanu, C.A. (2008) Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib. Journal of Clinical Oncology, 26, 40474048.
  • Badr, G., Lefevre, E.A. & Mohany, M. (2011) Thymoquinone inhibits the CXCL12-induced chemotaxis of multiple myeloma cells and increases their susceptibility to Fas-mediated apoptosis. PLoS ONE, 6, e23741.
  • Beck, B., Driessens, G., Goossens, S., Youssef, K.K., Kuchnio, A., Caauwe, A., Sotiropoulou, P.A., Loges, S., Lapouge, G., Candi, A., Mascre, G., Drogat, B., Dekoninck, S., Haigh, J.J., Carmeliet, P. & Blanpain, C. (2011) A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature, 478, 399403.
  • Benitah, S.A. (2011) Tumour biology: skin-cancer stem cells outwitted. Nature, 478, 329330.
  • Bossy-Wetzel, E., Newmeyer, D.D. & Green, D.R. (1998) Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO Journal, 17, 3749.
  • Burger, M., Hartmann, T., Krome, M., Rawluk, J., Tamamura, H., Fujii, N., Kipps, T.J. & Burger, J.A. (2005) Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood, 106, 18241830.
  • Calimeri, T., Battista, E., Conforti, F., Neri, P., Di Martino, M.T., Rossi, M., Foresta, U., Piro, E., Ferrara, F., Amorosi, A., Bahlis, N., Anderson, K.C., Munshi, N., Tagliaferri, P., Causa, F. & Tassone, P. (2011) A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia, 25, 707711.
  • Chauhan, D., Singh, A., Brahmandam, M., Podar, K., Hideshima, T., Richardson, P., Munshi, N., Palladino, M.A. & Anderson, K.C. (2008) Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood, 111, 16541664.
  • Chou, T.C. (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Research, 70, 440446.
  • DeWeerdt, S. (2011) Animal models: towards a myeloma mouse. Nature, 480, S3839.
  • Edwards, C.M., Lwin, S.T., Fowler, J.A., Oyajobi, B.O., Zhuang, J., Bates, A.L. & Mundy, G.R. (2009) Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo. American Journal of Hematology, 84, 268272.
  • Fan, F., Schimming, A., Jaeger, D. & Podar, K. (2012) Targeting the tumor microenvironment: focus on angiogenesis. Journal of oncology, 2012, 281261.
  • Fuchida, S.I., Shimazaki, C., Hirai, H., Akamatsu, S., Yamada, N., Uchida, R., Okano, A., Okamoto, M., Inaba, T. & Taniwaki, M. (2008) The effects of thalidomide on chemotactic migration of multiple myeloma cell lines. International journal of laboratory hematology, 30, 220229.
  • Goldstein, J.C., Waterhouse, N.J., Juin, P., Evan, G.I. & Green, D.R. (2000) The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nature Cell Biology, 2, 156162.
  • Goldstein, J.C., Munoz-Pinedo, C., Ricci, J.E., Adams, S.R., Kelekar, A., Schuler, M., Tsien, R.Y. & Green, D.R. (2005) Cytochrome c is released in a single step during apoptosis. Cell Death and Differentiation, 12, 453462.
  • Hideshima, T. & Anderson, K.C. (2011) Novel therapies in MM: from the aspect of preclinical studies. International Journal of Hematology, 94, 344354.
  • Hideshima, T., Chauhan, D., Podar, K., Schlossman, R.L., Richardson, P. & Anderson, K.C. (2001a) Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Seminars in Oncology, 28, 607612.
  • Hideshima, T., Richardson, P., Chauhan, D., Palombella, V.J., Elliott, P.J., Adams, J. & Anderson, K.C. (2001b) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Research, 61, 30713076.
  • Hideshima, T., Ikeda, H., Chauhan, D., Okawa, Y., Raje, N., Podar, K., Mitsiades, C., Munshi, N.C., Richardson, P.G., Carrasco, R.D. & Anderson, K.C. (2009) Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood, 114, 10461052.
  • Kyle, R.A. & Rajkumar, S.V. (2009) Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia, 23, 39.
  • LeBlanc, R., Catley, L.P., Hideshima, T., Lentzsch, S., Mitsiades, C.S., Mitsiades, N., Neuberg, D., Goloubeva, O., Pien, C.S., Adams, J., Gupta, D., Richardson, P.G., Munshi, N.C. & Anderson, K.C. (2002) Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Research, 62, 49965000.
  • Menu, E., Braet, F., Timmers, M., Van Riet, I., Van Camp, B. & Vanderkerken, K. (2002) The F-actin content of multiple myeloma cells as a measure of their migration. Annals of the New York Academy of Sciences, 973, 124136.
  • Miller, A.A., Murry, D.J., Owzar, K., Hollis, D.R., Kennedy, E.B., Abou-Alfa, G., Desai, A., Hwang, J., Villalona-Calero, M.A., Dees, E.C., Lewis, L.D., Fakih, M.G., Edelman, M.J., Millard, F., Frank, R.C., Hohl, R.J. & Ratain, M.J. (2009) Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. Journal of Clinical Oncology, 27, 18001805.
  • Moller, C., Stromberg, T., Juremalm, M., Nilsson, K. & Nilsson, G. (2003) Expression and function of chemokine receptors in human multiple myeloma. Leukemia, 17, 203210.
  • Ngo, H.T., Azab, A.K., Farag, M., Jia, X., Melhem, M.M., Runnels, J., Roccaro, A.M., Azab, F., Sacco, A., Leleu, X., Anderson, K.C. & Ghobrial, I.M. (2009) Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia. Clinical Cancer Research, 15, 60356041.
  • Ramakrishnan, V., Timm, M., Haug, J.L., Kimlinger, T.K., Wellik, L.E., Witzig, T.E., Rajkumar, S.V., Adjei, A.A. & Kumar, S. (2010) Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene, 29, 11901202.
  • Renz, A., Berdel, W.E., Kreuter, M., Belka, C., Schulze-Osthoff, K. & Los, M. (2001) Rapid extracellular release of cytochrome c is specific for apoptosis and marks cell death in vivo. Blood, 98, 15421548.
  • Rini, B.I. (2006) Sorafenib. Expert Opinion on Pharmacotherapy, 7, 453461.
  • Schüler, J., Wider, D., Pfeifer, D., Udi, J., Fiebig, H.-H., Wäsch, R. & Engelhardt, M. (2009) Antitumor Activity of Novel Anti-MM Agents and Combinations, the Proteasome Inhibitor Bortezomib and Multikinase Inhibitor Sorafenib, Both Applied as Monotherapy and in Combination in NOD/SCID-IL2-Receptor-Gamma-chain -/- (NSG) Mice Using a Intratibial Tumor Dissemination approach. Blood, 114, Abstract 4912
  • Shammas, M.A., Neri, P., Koley, H., Batchu, R.B., Bertheau, R.C., Munshi, V., Prabhala, R., Fulciniti, M., Tai, Y.T., Treon, S.P., Goyal, R.K., Anderson, K.C. & Munshi, N.C. (2006) Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood, 108, 28042810.
  • Strumberg, D., Clark, J.W., Awada, A., Moore, M.J., Richly, H., Hendlisz, A., Hirte, H.W., Eder, J.P., Lenz, H.J. & Schwartz, B. (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist, 12, 426437.
  • Tassone, P., Neri, P., Burger, R., Di Martino, M.T., Leone, E., Amodio, N. & Tagliaferri, P. (2012) Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma. Curr Cancer Drug Targets.
  • Teo, S.K., Stirling, D.I. & Zeldis, J.B. (2005) Thalidomide as a novel therapeutic agent: new uses for an old product. Drug discovery today, 10, 107114.
  • Udi, J., Wider, D., Kleber, M., Ihorst, G., Muller, A., Wasch, R. & Engelhardt, M. (2011) Early and mature endothelial progenitors and VEGFR2 + -cells in multiple myeloma: association with disease characteristics and variation in different cell compartments. Leukemia Research, 35, 12651268.
  • Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R.A., Schwartz, B., Simantov, R. & Kelley, S. (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Reviews. Drug Discovery, 5, 835844.
  • Yu, C., Friday, B.B., Lai, J.P., Yang, L., Sarkaria, J., Kay, N.E., Carter, C.A., Roberts, L.R., Kaufmann, S.H. & Adjei, A.A. (2006) Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Molecular Cancer Therapeutics, 5, 23782387.
  • Zhu, Y.X., Braggio, E., Shi, C.X., Bruins, L.A., Schmidt, J.E., Van Wier, S., Chang, X.B., Bjorklund, C.C., Fonseca, R., Bergsagel, P.L., Orlowski, R.Z. & Stewart, A.K. (2011) Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood, 118, 47714779.
  • Ziegler, U. & Groscurth, P. (2004) Morphological features of cell death. News in Physiological Sciences, 19, 124128.
  • Zlei, M., Egert, S., Wider, D., Ihorst, G., Wasch, R. & Engelhardt, M. (2007) Characterization of in vitro growth of multiple myeloma cells. Experimental Hematology, 35, 15501561.